Stock Library / CORT

CORT Unclassified Latest YouTube: Q2 2026 Published 2026-08-03

CORT

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Corcept (CORT): +27% On A Huge Beat — But The Guide Needs Lifyorli To Triple. Is CORT a Buy?

Published 2026-08-03

Open YouTube Spotify Show Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-03

Podcast available

Yes

Current price

$112.80

-3.96 (-3.39%)

Trailing / Forward P/E

250.67x

Forward: 24.97x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

31.7%

Earnings: 24.1%

Margins

16.1% op

Gross: 98.3% · Net: 6.6%

Balance sheet

2.86x current

Debt / Equity: 1.3

52-week range / Beta

$28.66 - $122.21

Beta: 0.46

Analyst target

$135.25

Upside: 19.9%

Cash / shareholder return

0.63% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: 17.25x

Return on equity: 8.2%

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Price chart

Market context for CORT

Competitive view

CORT vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

CORT latest YouTube video thumbnail

CORT

CORT

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

SS&C Technologies Holdings Inc. latest YouTube video thumbnail

SS&C Technologies Holdings Inc.

SSNC

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.

Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.

Danaher Corporation latest YouTube video thumbnail

Danaher Corporation

DHR

YouTube Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

CORT

$12.19B

CORT

SSNC

$18.63B

SS&C Technologies Holdings Inc.

DHR

$138.84B

Danaher Corporation

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

CORT

250.7x

CORT

SSNC

22.8x

SS&C Technologies Holdings Inc.

DHR

35.1x

Danaher Corporation

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

CORT

25.0x

CORT

SSNC

10.3x

SS&C Technologies Holdings Inc.

DHR

21.2x

Danaher Corporation

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

CORT

31.7%

CORT

SSNC

10.3%

SS&C Technologies Holdings Inc.

DHR

5.5%

Danaher Corporation

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

CORT

24.1%

CORT

SSNC

34.7%

SS&C Technologies Holdings Inc.

DHR

59.7%

Danaher Corporation

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

CORT

16.1%

CORT

SSNC

24.6%

SS&C Technologies Holdings Inc.

DHR

19.8%

Danaher Corporation

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

CORT

98.3%

CORT

SSNC

48.1%

SS&C Technologies Holdings Inc.

DHR

58.8%

Danaher Corporation

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

CORT

6.6%

CORT

SSNC

13.2%

SS&C Technologies Holdings Inc.

DHR

15.9%

Danaher Corporation

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

CORT

8.2%

CORT

SSNC

12.6%

SS&C Technologies Holdings Inc.

DHR

7.6%

Danaher Corporation

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

CORT

0.6%

CORT

SSNC

7.0%

SS&C Technologies Holdings Inc.

DHR

3.1%

Danaher Corporation

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

CORT

1.33x

CORT

SSNC

115.90x

SS&C Technologies Holdings Inc.

DHR

52.97x

Danaher Corporation

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

CORT

2.86x

CORT

SSNC

1.06x

SS&C Technologies Holdings Inc.

DHR

1.65x

Danaher Corporation

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

CORT

0.46

CORT

SSNC

1.09

SS&C Technologies Holdings Inc.

DHR

0.80

Danaher Corporation

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

CORT

—

CORT

SSNC

0.7%

SS&C Technologies Holdings Inc.

DHR

0.7%

Danaher Corporation

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

CORT

19.9%

CORT

SSNC

16.3%

SS&C Technologies Holdings Inc.

DHR

15.4%

Danaher Corporation

Related research

Non-quarter videos featuring CORT

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-02

Corcept (CORT) Jumped 27% — But The Guide Needs Lifyorli To Triple #shorts

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for CORT

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-03

Published youtube podcast complete

Corcept (CORT): +27% On A Huge Beat — But The Guide Needs Lifyorli To Triple. Is CORT a Buy?

Quarterly earnings-analysis entry for CORT. Use the links on the right to open the video or podcast episode.

YouTube Spotify Show Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music